Human Immunodeficiency Virus – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
The HIV therapy market is crowded with many approved antiretroviral therapies (ARVs). Growth in this market is being driven by the increasing acceptance of new, high-priced ARVs, particularly the latest single-tablet regimens (STRs), which have enhanced profiles (e.g., improved safety and tolerability, lower pill burden). The introduction of single-pill nuc-sparing and nuc-reduced regimens (e.g., ViiV’s Juluca and Dovato), which have a lower long-term risk of comorbidities, may expand treatment options and allow preferential prescribing to HIV patients who are compliant with their treatment regimens. In addition, the approvals of ViiV’s Cabenuva in 2021 and Apretude in 2022 have ushered in a new era of long-acting regimens that will help eliminate the requirement for lifelong daily pills. Finally, a large and aging predominantly viremic patient population, whose requirements will shift to treatment of their comorbidities as their HIV infections are well managed, will create new commercial opportunities. This claims data analysis offers insight into the current treatment landscape and physicians’ prescribing practices in HIV.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed HIV patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed HIV patients?
- How have Biktarvy, Dovato, Juluca, Symtuza, Cabenuva, and others been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of HIV patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of HIV patients are treated with STRs versus multiple-tablet regimens? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key drugs: Biktarvy, Dovato, Juluca, Symtuza, Delstrigo, Rukobia, Trogarzo, Cabenuva, Vocabria, Apretude
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Table of contents
- Human Immunodeficiency Virus - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
- Treatment Algorithms CDA Human Immunodeficiency Virus US March 2023
- Treatment Algorithms CDA Human Immunodeficiency Virus 2023 Dashboard
Muthana Sweis, M.P.H., Healthcare Research & Data Analyst, Infectious, Niche, and Rare Diseases. Muthana conducts primary and secondary research for a range of indications and authors reports related to his findings. He earned his master’s degree in public health from DePaul University.